Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

Fate Therapeutics (FATE) announced that management will participate in two investor conferences during the fourth quarter of 2026.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Fate Therapeutics (FATE) announced that management will participate in two investor conferences during the fourth quarter of 2026.

The Jefferies Global Healthcare Conference runs November 16–19 in London, UK, and the Piper Sandler 38th Annual Healthcare Conference runs December 1–3 in New York, NY. The company may participate in a presentation or fireside chat at these conferences.

Key Terms

ipsc

1 terms

ipsc technical

"induced pluripotent stem cell (iPSC)-derived cellular immunotherapies"

Induced pluripotent stem cells (iPSCs) are ordinary adult cells that scientists have reprogrammed back into a versatile, embryonic-like state so they can become many different cell types. Think of them as factory-reset cells that can be turned into heart, nerve, or blood cells for testing drugs, modeling diseases, or developing cell therapies. For investors, iPSCs signal potential high-reward opportunities in new treatments and research tools but also carry technical, manufacturing and regulatory risks that affect commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/01/2026 - 07:00 AM

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the fourth quarter of 2026.

2026 Jefferies Global Healthcare Conference

Location: London, UK

Date: November 16^th – 19^th

Piper Sandler 38^th Annual Healthcare Conference

Location: New York, NY

Date: December 1^st – 3^rd

The Company may participate in a presentation or a fireside chat at these conferences. When available, a live webcast will be accessible under “Events & Presentations” on the Investors section of the Company’s website at www.fatetherapeutics.com. An archived replay of the webcast will be available for 30 days following the event.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:

Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com